Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Person › Details

Ali Tehrani (Zymeworks Inc.)

Tehrani, Ali (Zymeworks 201510 CEO)


Organisation Organisation Zymeworks Inc.
  Group Zymeworks (Group)
Product Product bispecific antibody

ProBioGen AG. (10/14/15). "Press Release: Zymeworks Contracts ProBioGen for Bi-specific GlymaxX Antibody Cell Line Development. Cancer Antibody with Enhanced ADCC Potency to Be Produced". Berlin & Vancouver, BC.

ProBioGen AG, a leading specialist for contract development and manufacturing of complex glycoproteins, and Zymeworks Inc., a world-leading antibody therapeutics development company, today jointly announced signing an agreement under which ProBioGen will complete cell line development of a Zymeworks bi-specific antibody product candidate, applying its GlymaxX® Technology to enhance antibody-dependent cell-mediated cytotoxicity (ADCC).

ProBioGen’s CSO, Dr. Volker Sandig, commented: “We have been working productively with Zymeworks for some time already and look forward to contributing to the success of Zymeworks’ Azymetric™ bi-specific antibody platform. Our proprietary CHO expression platform is ideally suited for the expression of bi-specific antibodies with high purities and expression titers. The implementation of our innovative GlymaxX® technology for enhanced cancer cell killing underlines the flexibility of our expression platforms’ tool box approach.”

Dr. Ali Tehrani, Zymeworks’ President and CEO said: “We believe that biotherapeutics developed using the Azymetric™ platform have the potential to create game-changing treatment options for patients with unmet medical needs. Our productive partnership with ProBioGen and their highly skilled team will help advance one of Zymeworks’ therapeutic programs into the clinic. The incorporation of the GlymaxX® technology is one of the key components in enhancing the efficacy of this therapeutic candidate."

ProBioGen’s CEO, Dr. Wieland Wolf, added: “We are very pleased to work with Zymeworks as a biopharmaceutical company with world-wide recognition for their innovative and potentially life-changing therapeutic candidates. Given our established working relationship, we are confident that together we will help move highly efficacious bi-specific antibody therapeutics towards clinical validation.”


About ProBioGen AG –

ProBioGen is a specialist for developing and manufacturing complex therapeutic glycoproteins. Combining both state-of-the-art development platforms together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA). ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.

About Zymeworks –

Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. The company’s novel Azymetric™ and AlbuCORE™ platforms, and its proprietary ZymeCAD™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. More information on Zymeworks can be found at

About GlymaxX® -

The GlymaxX® technology, developed by ProBioGen, prevents the addition of the sugar “fucose” to the N-linked antibody carbohydrate part by antibody producing cells. The absence of fucose enhances ADCC (Antibody-dependent cell-mediated cytotoxicity). The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which deflects the cellular pathway of fucose biosynthesis. Moreover, GlymaxX® cell lines can be two cell lines in one: They can either produce afucosylated antibodies, or, by adding fucose to the medium, stably produce fully fucosylated antibodies. The GlymaxX® technology is universally applicable, simple and potent, and can be rapidly applied to any existing antibody producer cell line, any new cell line development or to entire expression platforms. ProBioGen offers this technology royalty-free to third parties.

Contact ProBioGen:

Dr. Gabriele Schneider
VP Business Development
ProBioGen AG
Goethestr. 54
13086 Berlin, Germany
Phone: +49 (0)30 924 006-0
Email: info(at)

Contact Zymeworks:

Dr. David Poon
Sr. Director, External R&D and Alliances
Zymeworks Inc.
540-1385 West 8th Ave
Vancouver BC Canada V6H 3V9
Phone: +1 (604) 678-1388
Email: info(at)

Record changed: 2017-04-09


Picture [LSE] – The Business Web Portal 650x65px

More documents for Ali Tehrani

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top